• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Polysomnography May Help Prevent Unnecessary Surgery in Children With Sleep-Disordered Breathing

Article

Nearly 45% of children who underwent diagnostic polysomnography (PSG) for obstructive sleep-disordered breathing were found to have normal sleep studies, warranting greater consideration of PSG to manage adverse sleep symptoms in children and potentially prevent unnecessary surgery.

Among children who underwent diagnostic polysomnography (PSG) for obstructive sleep-disordered breathing (oSDB), nearly 45% were found to have no signs of obstructive sleep apnea (OSA), with larger tonsil size associated with greater risk of OSA, according to study findings published last week in Annals of Otology, Rhinology & Laryngology.

As researchers highlight, oSDB is a common condition in pediatric populations that can range in severity from snoring to OSA. Notably, if medical or other nonsurgical treatments prove unsuccessful in managing potential OSA, adenotonsillectomy is the first-line surgical treatment for children, as the most common cause of obstruction is adenotonsillar hypertrophy.

“Careful identification of surgical candidates is essential as adenotonsillectomy is not without risk….[H]emorrhage and respiratory compromise are complications that can occur after adenotonsillectomy,” noted the study authors.

Although PSG is the gold standard for diagnosis of OSA, researchers say that guidelines for preoperative PSG assessment for children potentially undergoing adenotonsillectomy varies. Following American Academy of Otolaryngology-Head and Neck Surgery guidelines, they sought to determine the prevalence and characteristics of children with normal elective PSG for oSDB.

“Our hypothesis is that there will be a significant amount of reportedly symptomatic children who do not have OSA by PSG who would have otherwise had adenotonsillectomy based on symptoms and exam alone,” they explained.

Researchers conducted a retrospective cohort study recruiting 456 patients aged 2 to 18 years (mean [SD] age, 5.66 [3.19] years; 57.7% boys) who underwent diagnostic PSG for oSDB ordered by the otolaryngology department at Boston Medical Center between 2012 and 2018.

Participants’ demographic factors (age, gender, race, ethnicity, language, insurance status) and clinical findings (symptom severity, tonsil size) were recorded, with data analyzed via univariate and multivariate analysis.

Of the study cohort, 204 patients (44.7%) had no OSA based on the Apnea Hypopnea Index (AHI); these participants’ PSG indicated an AHI score less than 2. Additionally, children with a larger tonsil size, compared with those with a medium tonsil size, were indicated to be 3.18 times more likely to be diagnosed with OSA (95% CI, 1.64-6.19) when adjusting for symptoms, age category, and race (P = .0007).

In further distinguishing pediatric populations at risk of OSA, children ages 4 to 6 years were less likely to be diagnosed with OSA compared with children aged 2 to 3 years (odds ratio [OR], 0.25; 95% CI, 0.12-1.54), adjusting for symptoms, tonsil size, and race (P = .0011). White children were also less likely to be diagnosed with OSA compared with Black children (OR, 0.28; 95% CI, 0.14-0.57), adjusting for symptoms, tonsil size, and age category (P = .0004).

“This research demonstrates that obtaining sleep studies in otherwise healthy children with SDB can affect management decisions, and they should be discussed with families with a focus on patient centered decision making,” concluded the study authors.

Reference

Abraham EJ, Bains A, Rubin BR, Cohen MB, Levi JR. Predictors of a normal sleep study in healthy children with sleep disordered breathing symptoms. Ann Otol Rhinol Laryngol. Published online February 5, 2021. doi:10.1177/0003489421990156

Related Videos
Michael Thorpy, MD, Albert Einstein College of Medicine and Montefiore Medical Center.
Dr Michael Thorpy
Dr. Michael Thorpy
Sheila Garland, PhD, MSc, Memorial University
Dayna Johnson, PhD, MPH, MSW, MS, Rollins School of Public Health at Emory University
Judite Blanc, PhD, Miller School of Medicine/University of Miami
Judite Blanc, PhD, Miller School of Medicine/University of Miami
Andrew McHill, PhD, Oregon Health and Science University
Dayna Johnson, PhD, MPH, MSW, MS, Rollins School of Public Health at Emory University
Sheila Garland, PhD, MSc, Memorial University
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.